MHApp is back....

/

I’d like to inform you, that after years (literally!) of re-programming the MHApp is finally back in the AppStore.
The app is a complete re-write and presents in a refreshed user interface.

https://apps.apple.com/app/mhapp-malignant-hyperthermia/id392766134

Please report any inconsistencies, problems, errors etc. to me!

As the income from the paid app was very low (a couple of hundred dollars per year) and never even closely compensated for the workload, I have decided to have it as a free app.

hope you like it!

ps: it is currently only in English. German will follow very soon.

Attachment0.jpeg

COVID-19 and EMHG Meeting 2020, Nijmegen

/

The local organising committee and EMHG Executive Committee recognise that uncertainty surrounding the potential consequences of COVID-19 includes the potential for restrictions on travel, meetings and leave from hospital duties. Currently, there are no reasons to think that Nijmegen might be a high-risk location for COVID-19 but should the situation change we will be guided by the authorities in the Netherlands. We would like to encourage those who have registered, or wish to register, to pay their registration fee as soon as possible. The EMHG guarantees full reimbursement of the registration fee if the meeting is cancelled or you receive advice (from your government or employer) that you should not travel.

 

If you are making travel arrangements we would suggest that you ensure you have travel insurance that will recover these costs should the meeting be cancelled or you are prevented from travelling by the COVID-19 situation. If you are unable to obtain such insurance, we would suggest you do not book your travel until the beginning of April when we hope the situation will be clearer.

Genetics: European molecular quality network (EMQN)

/

The European molecular quality network (EMQN) are excited to announce that RYR1 External Quality Assessment (EQA) scheme introduced in 2019 for laboratories performing analysis of variants in the RYR1 gene for related myopathies and malignant hyperthermia susceptibility is also available in 2020.

Although the deadline is already officially closed, late registrations are possible by contacting the EMQN office directly (office@emqn.org).

The RYR1 EQA scheme is designed to test the whole analytical process. Three DNA samples will be distributed to participating laboratories in January 2020 for genetic analysis with case scenarios, the samples are suitable for sequencing and copy number analysis. Clinical reports from the participating laboratories will be evaluated for three elements; genotyping, interpretation, and clerical accuracy by a panel of expert peer assessors.

Please see the EMQN website (https://www.emqn.org) or contact office@emqn.org for further information.

Prizes at the 2019 annual meeting

/

The EMHG is proud to announce the following prize winners at the 2019 annual meeting in Potsdam

Best basic research presentation

Vikas Kaura from Leeds, UK

“Enhanced Sarcolemmal CalciumInflux in Malignant HyperthermiaSusceptible Mice and Humans”

IMG_6382.jpg

Best clinical presentation

Sebastian Heiderich from Hannover, Germany

“Trigger-free long duration minimalflow ventilation using activated charcoal filters"

IMG_6379.jpg

Presentation award from the public

Paul D. Allen from Leeds UK

“Clinical MH can be prevented with non-depolarizing neuromuscular blockers”

IMG_6385.jpg

Genetics: European molecular quality network (EMQN)

/

The European molecular quality network (EMQN) are excited to announce that they are introducing a brand new External Quality Assessment (EQA) scheme in 2019 for laboratories performing analysis of variants in the RYR1 gene for related myopathies and malignant hyperthermia susceptibility.

As the 2019 scheme is a pilot scheme, the scheme is subsidised and there is a reduced cost of £100 for registration. Participation is available for 30 laboratories for the 2019 RYR1 pilot scheme, registration is now open and will close on the 30th November 2018.

The RYR1 EQA scheme is designed to test the whole analytical process. Three DNA samples will be distributed to participating laboratories in January 2019 for genetic analysis with case scenarios, the samples are suitable for sequencing and copy number analysis. Clinical reports from the participating laboratories will be evaluated for three elements; genotyping, interpretation, and clerical accuracy by a panel of expert peer assessors.

This is the first EQA scheme offered for RYR1 testing, and we look forward to working with laboratories to harmonise and improve the quality of RYR1 testing globally.

Please see the EMQN website (https://www.emqn.org) or contact office@emqn.org for further information.